Pharming Group (PHAR) Competitors

$16.17 -0.22 (-1.34%)

Closing price 04:00 PM Eastern

Extended Trading

$16.23 +0.06 (+0.37%)

As of 04:10 PM Eastern

PHAR vs. LEGN, INDV, ORKA, CRNX, and AMRX

Should you be buying Pharming Group stock or one of its competitors? The main competitors of Pharming Group include Legend Biotech (LEGN), Indivior (INDV), Oruka Therapeutics (ORKA), Crinetics Pharmaceuticals (CRNX), and Amneal Pharmaceuticals (AMRX). These companies are all part of the "pharmaceutical products" industry.

How does Pharming Group compare to Legend Biotech?

Pharming Group (NASDAQ:PHAR) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

: In the previous week, Legend Biotech had 5 more articles in the media than Pharming Group. MarketBeat recorded 8 mentions for Legend Biotech and 3 mentions for Pharming Group. Pharming Group's average media sentiment score of 0.95 beat Legend Biotech's score of 0.22 indicating that Pharming Group is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pharming Group
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Legend Biotech
2 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Pharming Group has a beta of 0.04, indicating that its stock price is 96% less volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500.
: Pharming Group has a net margin of 0.71% compared to Legend Biotech's net margin of -28.86%. Pharming Group's return on equity of 1.08% beat Legend Biotech's return on equity.
Company Net Margins Return on Equity Return on Assets
Pharming Group 0.71% 1.08% 0.59%
Legend Biotech -28.86% -21.93% -13.21%
: Pharming Group has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pharming Group $376.13M 3.04 $2.85M $0.01 1,617.00
Legend Biotech $1.03B 5.13 -$296.80M -$0.80 N/A
: 0.0% of Pharming Group shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by company insiders. Comparatively, 0.0% of Legend Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
: Pharming Group presently has a consensus target price of $38.33, suggesting a potential upside of 137.06%. Legend Biotech has a consensus target price of $58.31, suggesting a potential upside of 104.52%. Given Pharming Group's higher possible upside, analysts plainly believe Pharming Group is more favorable than Legend Biotech.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pharming Group
0 Sell rating(s)
2 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.60
Legend Biotech
1 Sell rating(s)

3 Hold rating(s)

11 Buy rating(s)

0 Strong Buy rating(s)
2.67

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharming Group	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Legend Biotech	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Pharming Group	0.71%	1.08%	0.59%
Legend Biotech	-28.86%	-21.93%	-13.21%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$376.13M	3.04	$2.85M	$0.01	1,617.00
Legend Biotech	$1.03B	5.13	-$296.80M	-$0.80	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Pharming Group beats Legend Biotech on 9 of the 16 factors compared between the two stocks.

How does Pharming Group compare to Indivior?

Indivior (NASDAQ:INDV) and Pharming Group (NASDAQ:PHAR) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

: Indivior has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Comparatively, Pharming Group has a beta of 0.04, suggesting that its stock price is 96% less volatile than the S&P 500.
: In the previous week, Indivior had 17 more articles in the media than Pharming Group. MarketBeat recorded 20 mentions for Indivior and 3 mentions for Pharming Group. Pharming Group's average media sentiment score of 0.95 beat Indivior's score of 0.81 indicating that Pharming Group is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Indivior
4 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Pharming Group
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Indivior currently has a consensus price target of $39.33, suggesting a potential downside of 0.65%. Pharming Group has a consensus price target of $38.33, suggesting a potential upside of 137.06%. Given Pharming Group's higher possible upside, analysts clearly believe Pharming Group is more favorable than Indivior.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Indivior
0 Sell rating(s)
1 Hold rating(s)

5 Buy rating(s)

1 Strong Buy rating(s)
3.00
Pharming Group
0 Sell rating(s)

2 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.60
: Indivior has a net margin of 19.44% compared to Pharming Group's net margin of 0.71%. Pharming Group's return on equity of 1.08% beat Indivior's return on equity.
Company Net Margins Return on Equity Return on Assets
Indivior 19.44% -219.26% 29.40%
Pharming Group 0.71% 1.08% 0.59%
: Indivior has higher revenue and earnings than Pharming Group. Indivior is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Indivior $1.24B 3.90 $210M $1.95 20.30
Pharming Group $376.13M 3.04 $2.85M $0.01 1,617.00
: 60.3% of Indivior shares are held by institutional investors. Comparatively, 0.0% of Pharming Group shares are held by institutional investors. 0.7% of Indivior shares are held by insiders. Comparatively, 2.1% of Pharming Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indivior	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharming Group	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Pharming Group	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60

Company	Net Margins	Return on Equity	Return on Assets
Indivior	19.44%	-219.26%	29.40%
Pharming Group	0.71%	1.08%	0.59%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.24B	3.90	$210M	$1.95	20.30
Pharming Group	$376.13M	3.04	$2.85M	$0.01	1,617.00

Summary

Indivior beats Pharming Group on 12 of the 17 factors compared between the two stocks.

How does Pharming Group compare to Oruka Therapeutics?

Oruka Therapeutics (NASDAQ:ORKA) and Pharming Group (NASDAQ:PHAR) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

: Oruka Therapeutics has a beta of -0.2, suggesting that its stock price is 120% less volatile than the S&P 500. Comparatively, Pharming Group has a beta of 0.04, suggesting that its stock price is 96% less volatile than the S&P 500.
: In the previous week, Oruka Therapeutics had 20 more articles in the media than Pharming Group. MarketBeat recorded 23 mentions for Oruka Therapeutics and 3 mentions for Pharming Group. Pharming Group's average media sentiment score of 0.95 beat Oruka Therapeutics' score of 0.74 indicating that Pharming Group is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oruka Therapeutics
7 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Pharming Group
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Oruka Therapeutics currently has a consensus price target of $120.80, suggesting a potential upside of 75.20%. Pharming Group has a consensus price target of $38.33, suggesting a potential upside of 137.06%. Given Pharming Group's higher possible upside, analysts clearly believe Pharming Group is more favorable than Oruka Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oruka Therapeutics
1 Sell rating(s)
0 Hold rating(s)

10 Buy rating(s)

0 Strong Buy rating(s)
2.82
Pharming Group
0 Sell rating(s)

2 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.60
: Pharming Group has a net margin of 0.71% compared to Oruka Therapeutics' net margin of 0.00%. Pharming Group's return on equity of 1.08% beat Oruka Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Oruka Therapeutics N/A -25.48% -24.34%
Pharming Group 0.71% 1.08% 0.59%
: Pharming Group has higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Oruka Therapeutics N/A N/A -$105.43M -$1.86 N/A
Pharming Group $376.13M 3.04 $2.85M $0.01 1,617.00
: 56.4% of Oruka Therapeutics shares are held by institutional investors. Comparatively, 0.0% of Pharming Group shares are held by institutional investors. 24.7% of Oruka Therapeutics shares are held by insiders. Comparatively, 2.1% of Pharming Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharming Group	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Pharming Group	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-25.48%	-24.34%
Pharming Group	0.71%	1.08%	0.59%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.86	N/A
Pharming Group	$376.13M	3.04	$2.85M	$0.01	1,617.00

Summary

Pharming Group beats Oruka Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Pharming Group compare to Crinetics Pharmaceuticals?

Pharming Group (NASDAQ:PHAR) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.

: 0.0% of Pharming Group shares are owned by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by insiders. Comparatively, 6.0% of Crinetics Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
: Pharming Group has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pharming Group $376.13M 3.04 $2.85M $0.01 1,617.00
Crinetics Pharmaceuticals $7.70M 558.30 -$465.32M -$4.94 N/A
: Pharming Group currently has a consensus price target of $38.33, suggesting a potential upside of 137.06%. Crinetics Pharmaceuticals has a consensus price target of $76.75, suggesting a potential upside of 88.34%. Given Pharming Group's higher possible upside, equities analysts clearly believe Pharming Group is more favorable than Crinetics Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pharming Group
0 Sell rating(s)
2 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.60
Crinetics Pharmaceuticals
1 Sell rating(s)

0 Hold rating(s)

8 Buy rating(s)

1 Strong Buy rating(s)
2.90
: Pharming Group has a net margin of 0.71% compared to Crinetics Pharmaceuticals' net margin of -6,046.22%. Pharming Group's return on equity of 1.08% beat Crinetics Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Pharming Group 0.71% 1.08% 0.59%
Crinetics Pharmaceuticals -6,046.22% -41.46% -37.43%
: Pharming Group has a beta of 0.04, indicating that its share price is 96% less volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500.
: In the previous week, Crinetics Pharmaceuticals had 9 more articles in the media than Pharming Group. MarketBeat recorded 12 mentions for Crinetics Pharmaceuticals and 3 mentions for Pharming Group. Crinetics Pharmaceuticals' average media sentiment score of 0.96 beat Pharming Group's score of 0.95 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pharming Group
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Crinetics Pharmaceuticals
5 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$376.13M	3.04	$2.85M	$0.01	1,617.00
Crinetics Pharmaceuticals	$7.70M	558.30	-$465.32M	-$4.94	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60
Crinetics Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Company	Net Margins	Return on Equity	Return on Assets
Pharming Group	0.71%	1.08%	0.59%
Crinetics Pharmaceuticals	-6,046.22%	-41.46%	-37.43%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharming Group	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Crinetics Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Crinetics Pharmaceuticals beats Pharming Group on 9 of the 17 factors compared between the two stocks.

How does Pharming Group compare to Amneal Pharmaceuticals?

Pharming Group (NASDAQ:PHAR) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.

: In the previous week, Amneal Pharmaceuticals had 4 more articles in the media than Pharming Group. MarketBeat recorded 7 mentions for Amneal Pharmaceuticals and 3 mentions for Pharming Group. Pharming Group's average media sentiment score of 0.95 beat Amneal Pharmaceuticals' score of 0.75 indicating that Pharming Group is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pharming Group
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Amneal Pharmaceuticals
3 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Pharming Group has a beta of 0.04, indicating that its share price is 96% less volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500.
: Amneal Pharmaceuticals has higher revenue and earnings than Pharming Group. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pharming Group $376.13M 3.04 $2.85M $0.01 1,617.00
Amneal Pharmaceuticals $3.02B 1.40 $72.06M $0.38 35.29
: 0.0% of Pharming Group shares are owned by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
: Amneal Pharmaceuticals has a net margin of 4.53% compared to Pharming Group's net margin of 0.71%. Pharming Group's return on equity of 1.08% beat Amneal Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Pharming Group 0.71% 1.08% 0.59%
Amneal Pharmaceuticals 4.53% -276.67% 7.60%
: Pharming Group currently has a consensus price target of $38.33, suggesting a potential upside of 137.06%. Amneal Pharmaceuticals has a consensus price target of $15.00, suggesting a potential upside of 11.86%. Given Pharming Group's higher possible upside, equities analysts clearly believe Pharming Group is more favorable than Amneal Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pharming Group
0 Sell rating(s)
2 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.60
Amneal Pharmaceuticals
0 Sell rating(s)

2 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.75

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharming Group	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amneal Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$376.13M	3.04	$2.85M	$0.01	1,617.00
Amneal Pharmaceuticals	$3.02B	1.40	$72.06M	$0.38	35.29

Company	Net Margins	Return on Equity	Return on Assets
Pharming Group	0.71%	1.08%	0.59%
Amneal Pharmaceuticals	4.53%	-276.67%	7.60%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Amneal Pharmaceuticals beats Pharming Group on 11 of the 16 factors compared between the two stocks.

Get Pharming Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHAR vs. The Competition

Export

Metric	Pharming Group	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.14B	$3.39B	$6.25B	$11.87B
Dividend Yield	N/A	2.20%	2.73%	5.21%
P/E Ratio	1,617.00	38.85	29.04	28.47
Price / Sales	3.04	155.53	476.61	60.94
Price / Cash	84.67	57.88	27.62	36.52
Price / Book	4.09	7.03	9.67	6.67
Net Income	$2.85M	$23.62M	$3.55B	$332.53M
7 Day Performance	-1.52%	3.67%	1.70%	2.01%
1 Month Performance	-2.71%	7.16%	5.62%	9.20%
1 Year Performance	75.28%	67.03%	34.42%	39.59%

Pharming Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHAR Pharming Group	4.4493 of 5 stars	$16.17 -1.3%	$38.33 +137.1%	N/A	$1.14B	$376.13M	1,617.00	280	News Coverage Upcoming Earnings
LEGN Legend Biotech	3.3318 of 5 stars	$23.18 -2.0%	$58.31 +151.6%	N/A	$4.27B	$1.03B	N/A	2,965	News Coverage Upcoming Earnings
INDV Indivior	2.8111 of 5 stars	$34.64 +1.0%	$39.33 +13.6%	N/A	$4.19B	$1.24B	20.96	1,051	News Coverage Earnings Report Analyst Revision High Trading Volume
ORKA Oruka Therapeutics	3.2499 of 5 stars	$83.13 +8.8%	$109.90 +32.2%	N/A	$4.17B	N/A	N/A	N/A
CRNX Crinetics Pharmaceuticals	3.3368 of 5 stars	$39.85 +3.2%	$76.63 +92.3%	N/A	$4.14B	$7.70M	N/A	210	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PHAR) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pharming Group (PHAR) Competitors

PHAR vs. LEGN, INDV, ORKA, CRNX, and AMRX

How does Pharming Group compare to Legend Biotech?

Summary

How does Pharming Group compare to Indivior?

Summary

How does Pharming Group compare to Oruka Therapeutics?

Summary

How does Pharming Group compare to Crinetics Pharmaceuticals?

Summary

How does Pharming Group compare to Amneal Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHAR vs. The Competition

Pharming Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pharming Group (PHAR) Competitors

PHAR vs. LEGN, INDV, ORKA, CRNX, and AMRX

How does Pharming Group compare to Legend Biotech?

Summary

How does Pharming Group compare to Indivior?

Summary

How does Pharming Group compare to Oruka Therapeutics?

Summary

How does Pharming Group compare to Crinetics Pharmaceuticals?

Summary

How does Pharming Group compare to Amneal Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHAR vs. The Competition

Pharming Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools